Compare ACHV & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHV | VWAV |
|---|---|---|
| Founded | N/A | 2024 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 139.7M |
| IPO Year | 2018 | N/A |
| Metric | ACHV | VWAV |
|---|---|---|
| Price | $4.59 | $5.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 474.6K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $2.06 |
| 52 Week High | $6.15 | $15.80 |
| Indicator | ACHV | VWAV |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 41.61 |
| Support Level | $4.09 | $4.72 |
| Resistance Level | $4.98 | $6.49 |
| Average True Range (ATR) | 0.40 | 0.42 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 7.56 | 15.60 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.